About the Book
Publisher's Note: Products purchased from Third Party sellers are not guaranteed by the publisher for quality, authenticity, or access to any online entitlements included with the product.
A COMPLETE INTRODUCTORY TEXT TO THE FIELD OF PHARMACOGENOMICSA Doody's Core Title for 2017!
The only pharmacogenomics resource to feature a global author team comprised of PharmDs, MDs, PhDs and social scientists, Pharmacogenomics offers an essential, highly accessible survey of this dynamic discipline. You will find thorough coverage of all need-to-know topics, from individual molecules to systemic diseases, plus anexamination of the latest technologies that are constantly reshaping the field. Pharmacogenomics is cohesively organized into two sections, the first of which reviewsbasic aspects of pharmacogenomics, including ethics, regulatory, science, and drug metabolism, along with a "mini" course in molecular genetics and testing. The second section highlights the practical application of pharmacogenomics in cardiovascular medicine, immunology, neurology, and other specialties.
FEATURES
Important overview of general pharmacogenomics and pharmacogenetics concepts, including geneticvariation in signal transduction and targets, plus a review of the genetic concepts of pharmacogenomics
Discussion of regulatory considerations in pharmacogenomics
Focus on the role of health care professionals along with a review of related privacy issues,as well as broader ethical, legal, and social considerations
In-depth chapters on drug metabolism and transporters
Practical, step-by-step guidance on public access to pharmacogenomic testing and patient counseling
Up-to-date coverage of non-genetic influences on pharmacogenomics
Emphasis on gene-drug interactions
Numerous tables and figures
Chapter-ending references
Concise learning objectives at the beginning of each chapter
Case studies to familiarize you with the clinical relevance of pharmacogenomics in each specialty
Table of Contents:
Section I. General Concepts
1. Developing Perspectives on Pharmacogenomics
2. Genetic Concepts of Pharmacogenomics: Basic Review of DNA, Genes, Polymorphisms, Haplotypes and Nomenclature
3. Analytical Methods to Identify Genetic Variations and Bioinformatics
4. Regulatory Considerations in Pharmacogenomics at EMA and US FDA
5. Ethical, Legal, and Social Issues Associated with Pharmacogenomics
6A. Pharmacogenetics of Cytochrome P450
6B. Phase II Drug-Metabolizing Enzymes
7. Drug Transporters
8. Nongenetic Influences on Drug Metabolism
9. Public Access to Pharmacogenomic Testing and Patient Counseling
10. Understanding the Use of Pharmacoeconomic Analysis to Assess the Economic Impact of Pharmacogenomic Testing
Section II. Clinical Application of Pharmacogenomics
11. Cardiovascular Pharmacogenomics
12. Pharmacogenomics and Pharmacogenetics for Infectious Diseases
13. Pharmacogenomics in Oncology
14. Psychiatry and Addiction Medicine
15. Immunology,Transplantation,and Vaccines
16. Pharmacogenomics in Neurology
17A. Pharmacogenomics of Gastrointestinal Drugs: Focus on Proton Pump Inhibitors
17B. Genomics and the Kidney
Index
About the Author :
Joseph S. Bertino Jr., Pharm.D. is an Associate Professor of Clinical Pharmacology in Medicine at the College of Physicians and Surgeons, Columbia University, New York, NY. His research interests are varied and include work with vaccines, antimicrobial pharmacokinetics and pharmacodynamics, treatment of hypertension, pharmacogenetics and pharmacogenomics. Dr. Bertino received the Pharm.D. degree from SUNY at Buffalo. He has published over 100 original research papers, review articles and book chapters. His publications have included work in the area of antimicrobial pharmacokinetics, pharmacodynamics and toxicity, drug-drug interactions, general clinical pharmacology, vaccine pharmacology and the application of pharmacogenetics to the drug development process.
Joseph D. Ma, PharmD is an Assistant Professor at the University of California San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences. He received his Pharmacy Doctorate from the University of California, San Francisco. He then completed a 2-year fellowship in clinical pharmacology at Bassett Healthcare, Cooperstown, NY. Upon fellowship completion, Dr. Ma was employed at Amgen, Inc. and was responsible for phase I protocol development and study operational and managerial functions. Dr. Ma joined UCSD in 2007. He serves as co-coordinator for the winter quarter Therapeutics course and for a spring quarter elective titled Drug Discovery, Development, and Commercialization. His research interests are in examining pharmacokinetic and pharmacodynamic variability and in the optimization of drugs as probes to phenotype drug-metabolizing enzyme activity.
Angela Kashuba, PharmD is an Associate Professor of Pharmacy at the University of North Carolina in Chappel Hill. Ms. Kashuba received two grants specifically on pharmcgenomics on the elderly.
C. Lindsay DeVane, Pharm.D. is Professor of Psychiatry and Behavioral Sciences and Vice Chair for Research in the Department of Psychiatry at the Medical University of South Carolina (MUSC) in Charleston, SC. He directs the Laboratory of Drug Disposition and Pharmacogenetics in the Darby Children’s Research Institute and oversees operation of the core laboratories of MUSC’s General Clinical Research Center.
Professor Uwe Fuhr MD, is Clinical Pharmacologist at University of Cologne, Cologne, Germany, Faculty of Medicine. He is a native of Saarbruecken, Germany, and attended Johann Wolfgang Goethe University in Frankfurt am Main, Germany, as an undergraduate in Medicine where he obtained state registration as a physician in 1987.
